Is there any synergic effect for coadministration of mitomycin C and halofuginone on the skin wound healing?
OBJECTIVE
This study compared the potencies of the antifibrotic agents mitomycin C (MMC) and halofuginone (HFN) and investigated whether coadministration of these agents produces synergic effects in an animal skin wound model.


METHODS
Twenty male Sprague-Dawley rats were used for this study. After a full-thickness excisional wound was made on the dorsum of each rat, each rat was treated with topical mitomycin, intraperitoneal HFN, or both. Wound surface areas were measured over time, and histologic analysis was performed after wounds healed completely.


RESULTS
The groups treated with MMC alone, HFN alone, and a combination of the two all exhibited delayed wound healing compared with the untreated group. Histologically, fibrosis and matrix metalloproteinase-2 expression were significantly inhibited in the treated groups. However, there were no gross or histologic differences between the MMC-treated group, the HFN-treated group, and the combination-treatment group.


CONCLUSIONS
Both MMC and HFN inhibited excessive fibrosis. However, there was no significant difference in the antifibrotic effects of MMC and HFN on surgically induced skin wounds. Moreover, combination treatment with both MMC and HFN failed to confer an additional antifibrotic effect on skin wounds when compared with treatment with MMC or HFN alone.
Yoon
Yeo-Hoon
YH
Department of Otolaryngology-Head and Neck Surgery, Cancer Research Institute, Research Institute for Medical Sciences, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
Rha
Ki Sang
KS
Kim
Dong Heon
DH
Kim
Eung-Hyub
EH
Kim
Jin Man
JM
Koo
Bon Seok
BS
D000287:Administration, Topical; D000477:Alkylating Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D004195:Disease Models, Animal; D004338:Drug Combinations; D004347:Drug Interactions; D007274:Injections, Intraperitoneal; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage / Q000494:pharmacology*; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology*; D052999:Quinazolinones / Q000008:administration & dosage / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012867:Skin / Q000293:injuries*; D014945:Wound Healing / Q000187:drug effects*
D000477:Alkylating Agents; D004338:Drug Combinations; D010880:Piperidines; D052999:Quinazolinones; D016685:Mitomycin; C010176:halofuginone